The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Discover how resolving MRI-detected inflammation improves clinical outcomes for aptients with axial spondyloarthritis.

TNF Pharmaceuticals (TNFA) announced that it has achieved a safety data milestone supporting expanded and longer-term clinical studies of its ...

3 TNF inhibitor drug category: the global market value for TNF inhibitors was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor ...

Walk down the street, and you see huge billboards and hoardings. There are no ad blockers for this media! Sure you may ignore them, but you can’t block them. :) We have spaced out our ads so ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Worries that ...

TNF blockers, which work by attaching to and impeding chemical messengers behind inflammation, have had a significant impact on the treatment of RA. They have also been linked to lymphoma among users.